Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Gut hormones in the treatment of short-bowel syndrome and intestinal failure

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Updates in weight loss surgery and gastrointestinal peptides

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Genetic and environmental origins of hypospadias

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Occupational causes of male infertility

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The physiology and timing of male puberty

    Publikation: Bidrag til tidsskriftReviewForskning

  5. Environmental chemicals and thyroid function: an update

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Repeated Metabolic Balance Studies in Patients With Short Bowel Syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

PURPOSE OF REVIEW: The approval of teduglutide, a recombinant analog of human glucagon-like peptide (GLP) 2, by the US Food and Drug Administration (Gattex) and the European Medicines Agency (Revestive) has illustrated the potential of selected gut hormones as treatments in patients with short-bowel syndrome and intestinal failure. Gut hormones may improve the structural and functional intestinal adaptation following intestinal resection by decreasing a rapid gastric emptying and hypersecretion, by increasing the intestinal blood flow, and by promoting intestinal growth. This review summarizes the findings from phase 2 and 3 teduglutide studies, and pilot studies employing GLP-1 and agonists for this orphan condition.

RECENT FINDINGS: In a 3-week, phase 2, metabolic balance study, teduglutide increased the intestinal wet weight absorption by approximately 700 g/day and reduced fecal energy losses by approximately 0.8 MJ/day (∼200 Kcal/day). In two subsequent 24-week, phase 3 studies, teduglutide reduced the need for parenteral support in the same magnitude. Adverse events were mainly of gastrointestinal origin and consistent with the known mechanism of action of teduglutide. Pilot studies suggest that GLP-1 may be less potent. Synergistic effects may be seen by co-treatment with GLP-2.

SUMMARY: Gut hormones promote intestinal adaptation and absorption, decreasing fecal losses, thereby decreasing or even eliminating the need for parenteral support. This will aid the intestinal rehabilitation in these severely disabled short-bowel syndrome patients.

OriginalsprogEngelsk
TidsskriftCurrent Opinion in Endocrinology, Diabetes and Obesity
Vol/bind22
Udgave nummer1
Sider (fra-til)14-20
Antal sider7
ISSN1752-296X
DOI
StatusUdgivet - feb. 2015

ID: 45955529